The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis
- PMID: 19822056
The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis
Abstract
During the last decade the economic burden of rheumatic diseases has been increasingly recognised. Even though more studies have been published on rheumatoid arthritis (RA) than ankylosing spondylitis (AS) sufficient data is available for comparison of some economic consequences. This overview addresses mainly the societal impact of RA and AS on (1) labour force participation, on (2) the costs of healthcare consumption and reduced productivity and on (3) health in terms of QALY.In order to examine labour force participation comparison with the general population is preferable. These studies demonstrate increased withdrawal from work in both diseases but more frequently in RA. Risk factors for reduced labour force participation in RA and AS are longer disease duration, lower education and unfavourable labour market conditions. The influence of the sex on employment depends on several factors such as the type of disease and the labour force participation of the general population.In RA overall mean direct costs of healthcare consumption and indirect costs of reduced productivity are above that of AS, particularly after long disease duration. Out-of-pocket expenditures costs were higher in females RA patients than in males while this was less clear in AS. The main cost driver in both diseases for all type of costs was reduced physical function.The societal valuation of health (utility) showed similar reductions of quality adjusted life years (QALYs) in RA and AS when compared with the general population.In conclusion, while the societal valuation of the impact of both diseases on health is similar, the decrease in worker participation is more pronounced in RA and direct as well as productivity costs are higher. However, since AS starts at an earlier age, the lifetime economic burden might be higher. There is a strong relation between physical function and each aspect of economic impact.
Similar articles
-
Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis.Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S118-23. Clin Exp Rheumatol. 2009. PMID: 19822057
-
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.J Rheumatol. 2000 Mar;27(3):613-22. J Rheumatol. 2000. PMID: 10743798
-
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.Ann Rheum Dis. 2006 Sep;65(9):1175-83. doi: 10.1136/ard.2005.046367. Epub 2006 Mar 15. Ann Rheum Dis. 2006. PMID: 16540552 Free PMC article.
-
Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis.Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S108-11. Clin Exp Rheumatol. 2009. PMID: 19822055 Review.
-
Ankylosing spondylitis: what is the cost to society, and can it be reduced?Best Pract Res Clin Rheumatol. 2002 Sep;16(4):691-705. doi: 10.1053/berh.2002.0244. Best Pract Res Clin Rheumatol. 2002. PMID: 12406435 Review.
Cited by
-
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.Cost Eff Resour Alloc. 2015 Oct 7;13:18. doi: 10.1186/s12962-015-0044-x. eCollection 2015. Cost Eff Resour Alloc. 2015. PMID: 26451133 Free PMC article.
-
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.RMD Open. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016. RMD Open. 2016. PMID: 27493791 Free PMC article.
-
The balance of tissue repair and remodeling in chronic arthritis.Nat Rev Rheumatol. 2011 Oct 18;7(12):700-7. doi: 10.1038/nrrheum.2011.156. Nat Rev Rheumatol. 2011. PMID: 22009331 Review.
-
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.Adv Ther. 2015 Aug;32(8):742-56. doi: 10.1007/s12325-015-0233-1. Epub 2015 Sep 5. Adv Ther. 2015. PMID: 26343027 Free PMC article.
-
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.Ann Rheum Dis. 2015 Jan;74(1):44-51. doi: 10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18. Ann Rheum Dis. 2015. PMID: 24942382 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials